Compare iShares MBS ETF (MBB) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs 22nd Century Group Inc — how do they compare? iShares MBS ETF trades at $89.75 (market cap $35.41B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: iShares MBS ETF is far larger — about 56959.5× 22nd Century Group Inc's market cap, and 22nd Century Group Inc is more actively traded (45,625 versus 5,388,525). Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and 22nd Century Group Inc for 32 Days on average.
| MBB | XXII | |
|---|---|---|
Market Cap | $35.41B | $621.67K |
Volume | 5,388,525 | 45,625 |
Sector | Fixed Income | Consumer Staples |
52-Week High | $96.91 | $483.00 |
52-Week Low | $89.09 | $0.80 |
Typical Hold Time | 96 Days | 32 Days |
Enterprise Value | — | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $89.79, up 0.64% with bearish technical signals from moving averages and ADX indicators. The ETF faces headwinds from rising intermediate-term rates and inflation pressures, with short interest surging 98.3% in September. Recent institutional buying by Corient Private Wealth and Baird Financial contrasts with technical weakness and negative analyst commentary on duration risk.
Outlook remains cautious due to interest rate sensitivity and convexity risks in mortgage-backed securities. The 5.68-year effective duration exposes MBB to Fed policy shifts, though Norway's $2.3 trillion sovereign fund rotation into MBS provides counterbalancing institutional support. Key risks include prepayment optionality and persistent inflation eroding real returns.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
